METABOLIC EFFECTS OF STATINS AND CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS
Abstract
Thus review presents the modern concept of atherosclerosis and its main pathophysiological mechanisms, such as lipid peroxidation and inflammation. The authors describe the underlying mechanisms of the statins’ influence on clinical manifestations of atherosclerosis, which are related to lipid-lowering, pleiotropic, and metabolic effects of statins. Complex metabolic influences of statins are also discussed, including their effects on insulin resistance, glycemia, lipid profile (triglycerides and high-density lipoprotein cholesterol), uric acid, and markers of inflammation and lipid peroxidation. Finally, the impact of statin therapy on major cardiovascular risk factors, such as arterial hypertension and obesity, is debated.
About the Authors
E. I. Yakovenko
Поликлиника № 96 СЗАО, Москва
Russian Federation
Polyclinic No. 96 , North-West Administrative District, Moscow
Russian Federation
Polyclinic No. 96 , North-West Administrative District, Moscow
M. N. Mamedov
ФГБУ Государстванный научно-исследовательский центр профилактической медицины Минздравсоцразвития РФ, Москва
Russian Federation
State Research Centre for Preventive Medicine, Moscow, Russia
Russian Federation
State Research Centre for Preventive Medicine, Moscow, Russia
References
1. Diagnostics and correction of infringements lipid an exchange for the purpose of preventive maintenance and atherosclerosis treatment. National clinical guidelines 2th ed. Silicea-Polygraf, Moscow 2009, p.528. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Сборник национальных клинических рекомендаций. 2 изд, под ред. Огановa Р.Г., Мамедовa М.Н. Из-во «Силицея-Полиграф», М. 2009; 528 с.)
2. Оgаnоv R.G. Demographic situation and cardiovascular diseases in Russia: ways of the decision of problems. Cardiovascular therapy and prevention 2007; 6 (8):7–14. Russian (Демографическая ситуация и сердечно-сосудистые заболевания в России: пути решения проблем. Кардиоваскулярная терапия и профилактика 2007; 6 (8): 7–14.)
3. All about cholesterol. The national report; under edition RAMN L.A. Bokerija i akademika RAMN R.G. Oganova.- Moscow: NCSSH im. A.N. Bakuleva RAMN, 2010. Russian (Все о холестерине. Национальный доклад; под ред. акад. РАМН Л.А. Бокерия и Р.Г. Оганова. Москва: НЦССХ им. А.Н. Бакулева РАМН, 2010).
4. Mamedov MN. Diagnostics, preventive maintenance and treatment of a diabetes and its complications (on materials ХХ World congress the International Federation of the Diabetes) Moscow: OOO RG «PRE100» 2010. Russian (Мамедов М.Н. Диагностика, профилактика и лечение сахарного диабета и его осложнений (по материалам ХХ Всемирного конгресcа Международной Федерации Диабета). Москва: ООО РГ «ПРЕ100»; 2010).
5. Alderman M.H. Serum Uric Acid As a Cardiovacular Risk Factor for Hart Disease. Current Hypertension Reports 2001; 3:184–189.
6. Steinberg D. The LDL modification hypothesis of aterogenesis: an update.J. Lipid Res. 2009; Suppl: 376–381.
7. Ignarro IJ, Lun W. Nitric oxide in the regulation of vascular function: an historical overview J Card Surg. 2002;17 (4): 301–306.
8. Ragino J.I. et al. Key laboratory-diagnostic biomarkers of a coronary atherosclerosis. Cardiology 2011; 3 (51):42–46. Russian (Рагино Ю.И. и др. Ключевые лабораторно- диагностические биомаркеры коронарного атеросклероза. Кардиология 2011; 3 (51): 42–46).
9. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008; 79 (3): 360–376.
10. Tatenkulova S.N., Belenkov Ju.N., Mareev V.Ju. et al. Influence statins on immune mechanisms of inflammatory reaction at CHF and an ischemic etiology. Serdechnaja nedostatochnost 2009; 10, № 2 (52):107–114. Russian (Татенкулова С. Н., Беленков Ю.Н., Мареев В.Ю. и др. Влияние статинов на иммунные механизмы воспалительной реакции при ХСН ишемической этиологии. Сердечная недостаточность. 2009; 10, № 2 (52):107–114).
11. Susekov A.V. Inhibitors GMK-KoA-reduktazy at secondary preventive maintenance of an atherosclerosis: 30 years later. Dislipidemia and atherosclerosis 2005; 7 (11):17–26. Russian (Сусеков А.В. Ингибиторы ГМК-КоА-редуктазы при вторичной профилактике атеросклероза: 30 лет спустя. Дислипидемии и атеросклероз. 2005; 7 (11):17–26).
12. Konstantinov V. A, Kuharchuk G.A. et al. Blood Lipids, an inflammation and an atherosclerosis – a new view on preventive maintenance in the light of results of recent clinical researches. Heart. 2009; 8 № 5 (49): 240–242. Russian (Константинов В.А., Кухарчук Г.А. и др. Липиды крови, воспаление и атеросклероз – новый взгляд на профилактику в свете результатов недавних клинических исследований. Сердце. 2009; 8 № 5 (49):240–242).
13. Astra Zeneka: Crestor outcomes study JUPITER closes early due to unequivocal evidence of benefit [press release] March 31, 2008.
14. Hanefeld M., Marx N., Pfutzner A. et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007; 23; 49 (3):290–7.
15. Devaraj S, Chan ЕJ. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006; 91 (11):4489–96.
16. Ridker PM, Danielson E, Fonseka FA. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359 (21):2195–2207.
17. Lee SJ, Qin H, Benveniste EN. The IFN- gamma-induced transcriptional program of the CIITA gene in inhibited by statins. Eur J Immunol. 2008; 38 (8):2325–2336.
18. Heeba G, Hassan MK, Khalifa M, et al. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc. Pharmacol. 2007; 50 (4): 391–398.
19. Singh U, Deveraj S, Jialal I. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol. 2008; 102 (3): 321–5.
20. Schwartz R, Osborne-Lawrence S, Hahner L et al. C-reactive protein downrequlates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res. 2007; 100 (10): 1452–1459.
21. Strey CH, Young JM, Lainchbury JH, et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with nonischaemic heart failure. Heat. 2006; 92 (11): 1603–1609.
22. Arutyunov G.P, Bylova N.A., Dzidzarija M.I. A insulinrezistens syndrome and HF – an unresolved problem. Serdechnaja nedostatochnost. 2009; 10, 3 (53):177–182. Russian (Арутюнов Г. П., Былова Н.А., Дзидзария М. И. Синдром инсулинрезистентности и ХСН – нерешенная проблема. Сердечная недостаточность. 2009; 10, 3 (53):177– 182).
23. Rugina M, Caras I, Jurcut R, et al. Sistemic inflammatory markers in patients with aortic sclerosis. Roum Arch Microbiol Immunol. 2007; 66 (1–2):10–16.
24. Ferrari LA, Mancini M, Celentano A, et al. Early changes of the arterial carotid wall in hyperinsulinemia, hypertriglyceridemia, versus hyperholesterolemia. Aterosclerosis 2003; 171 (2): 303–309.
25. Mamedov M.N, Oganov R.G. Postprandial hyperglycemia – a target for preventive maintenance of cardiovascular complications and a diabetes. Moscow: RPK «Vikas – print» 2010. Russian (Мамедов М.Н., Оганов Р.Г. Постпрандиальная гипергликемия – мишень для профилактики сердечно-сосудистых осложнений и сахарного диабета. Москва: РПК «Викас – принт»; 2010).
26. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011; 57 (14): 1535–45.
27. Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010; 55 (12):1209–16.
28. Otero M, Lago R, Lago F, et al. Leptin, from fat to inflammation: old question and new insights. FEBS Lett. 2005; 579:295–30.
29. Scherer PE. Adiponectin: its multiple roles. Diabetes UK, Diabetic Medicine. 2006; 23 (4):43.
30. Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease. AM J Kidney Dis. 1999; 33:225–234.
31. Lewandowski J, Sinski M, Bidiuk J, et al. Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res. 2010; 33 (10):1038–43.
32. СrouseJR 3rd , Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA. 2007; 2979120: 1344–1353.
33. Messerli FH, Pinto L, Tang SS, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapya – meta-analysis. Am J Cardiol. 2008; 101 (3): 319–25.
Review
For citations:
Yakovenko E.I., Mamedov M.N. METABOLIC EFFECTS OF STATINS AND CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS. Russian Journal of Cardiology. 2012;(2):85-90. (In Russ.)
Views:
498
Email this article 